Stent thrombosis and restenosis are of great clinical significance. We constructed a closed loop in vitro heparinized whole human blood circulation model for testing hemocompatibility of coronary stents. This model allows evaluation of human blood activation by blood-stent interaction in a well-controlled setting. Until now these interactions were studied in the highly coagulable pig coronary artery model.
Methods
We evaluated activation of the coagulation system and blood components by uncoated, heparin-coated, and silicon-carbide coated tantalum stents. The effects, measured by biochemical assays, were compared with stainless-steel stents. Also the inhibitory effect on platelet activation by indomethacin equal to the oral effect of 325 mg acetylsalicylic acid daily, was measured and visualized by scanning electron microscopy.
Results
Both activation of the coagulation system and platelets were counteracted by indomethacin, suggesting an important role for platelets in activation of the coagulation system in this model. Despite platelet activation by all stents, the SiC-coated tantalum stent demonstrates a significantly lower GpIIIa receptor-mediated platelet adhesion at the stent surface (21.7×103 counts per second/mg stent weight) compared to all other stents (stainless-steel 54.0, heparincoated 95.7 and uncoated 76.2×103 cps/mg). Also activated leukocytes demonstrated a significantly lower CD11b receptor-mediated adhesion at the SiC-coated stent (37.0×103 cps/mg) than at the stainless-steel stent (114.5×103 cps/mg).
Conclusions
Data from this in vitro circulation study show a significantly lower platelet and leukocyte adhesion at the surface of the SiC-coated tantalum stent than at the surface of stainless-steel stents or uncoated and heparin-coated tantalum stents.
FischmanDL, LeonMB, BaimDS, SchatzRA, SavageMP, PennI, DetreK, VeltriL, RicciD, NobuyoshiM.A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med1994;331(8):496–501.
2.
SerruysPW, de JaegereP, KiemeneijF, MacayaC, RutschW, HeyndrickxGR, EmanuelssonHU, MarcoJD, LegrandV, MaterneP.A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med1994;331(8):489–95.
3.
LahamRJ, CarrozzaJP, BergerC, CohenDJ, KuntzRE, BaimDS. Long-term (4- to 6-year) outcome of Palmaz-Schatz stenting: paucity of late clinical stent-related problems. J Am Coll Cardiol1996;28(4):820–6.
4.
EeckhoutE, KappenbergerL, GoyJL. Stents for intracoronary placement: current status and future directions. J Am Coll Cardiol1996;27(4):757–65.
5.
SteinhublSR, LincoffAM. Antithrombotic therapy with intracoronary stenting. Heart1997;78(2 Suppl):21–3.
6.
GershlickAH. Antiplatelet therapy following stent deployment. Heart1997;78(2 Suppl):24–6.
7.
SerruysPW, StraussBH, BeattKJ, BertrandME, PuelJ, RickardsAF, MeierB, GoyJJ, VogtP, KappenbergerL, et aI. Angiographic follow-up after placement of a self-expanding coronary-artery stent. N Engl J Med1991;324(1):13–7.
8.
HardhammarPA, van BeusekomHM, EmanuelssonHU, HofmaSH, AlbertssonPA, VerdouwPD, BoersmaE, SerruysPW. Reduction in thrombotic events with heparin-coated Palmaz-Schatz stents in normal porcine coronary arteries. Circulation1996;93(3):423–30.
9.
JenkinsJS, WebelR, LaughlinMH, RowlandSM, YoklavichMF, BransonK, ParkerJL, MyersPR. The effects of intravascular stents on vasomotion in porcine coronary arteries. J Invasive Cardiol1995;7:200–6.
10.
ScottNA, RobinsonKA, NunesGL, ThomasCN, VielK, KingSB, HarkerLA, RowlandSM, JumanI, CipollaGO. Comparison of the thrombogenicity of stainless steel and tantalum coronary stents. Am Heart J1995;129(5):866–72.
SernaDL, KingBO, HuhJ, JalalR, TranL, ChenJC. Evidence for selective degradation of platelet GP IIbIIIIa complex after prolonged in vitro ventricular assist. J Investig Med1998;46(6):279–83.
13.
SerruysPW, EmanuelssonHU, van der GiessenWJ, LunnAC, KiemeneijF, MacayaC, RutschW, HeyndrickxGR, SuryapranataH, LegrandV, . Heparin-coated Palmaz-Schatz stents in human coronary arteries. Early outcome of the Benestent-II Pilot Study. Circulation1996;93:412–22.
14.
BaleonR, BeyarR, ChierchiaS, de ScheerderI, HugenholtzPG, KiemeneijF, MeierB, MeyerJ, MonassierJP, WijnsW.Recommendations on stent manufacture, implantation and utilization. Study Group of the Working Group on Coronary Circulation. Eur Heart J1997;18(10):1536–47.
15.
ColomboA, HallP, NakamuraS, AlmagorY, MaielloL, MartiniG, GaglioneA, GoldbergSL, TobisJM. Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. Circulation1995;91(6):1676–88.
16.
GawazM, NeumannFJ, OttI, MayA, RudigerS, SchomigA.Changes in membrane glycoproteins of circulating platelets after coronary stent implantation. Heart1996;76(2):166–72.
OzbekC, HeiselA, GrossB, BayW, SchiefferH.Coronary implantation of silicone-carbide-coated Palmaz-Schatz stents in patients with high risk of stent thrombosis without oral anticoagulation. Cathet Cardiovasc Diagn1997;41(1):71–8.
19.
BeythienC, TerresW, HammCW. In vitro model to test the thrombogenicity of coronary stents. Thromb Res1994;75(6):581–9.
20.
SchumacherH, HuberFX, AulmannM, KallinowskiF, AllenbergJR. [Effect of endovascular surgery of infrarenal aortic aneurysms on circulating endothelial adhesion molecules, cytokines and proteinase inhibitors] Einfluss der endovaskularen Chirurgie infrarenaler Aortenaneurysmen auf zirkulierende endotheliale Adhasionsmolekule, Zytokine und Proteinaseinhibitoren. Langenbecks Arch Chir Suppl Kongressbd1997;114:15–9.
21.
de HaanJ, BoonstraPW, MonninkSHJ, EbelsT, van OeverenW.Retransfusion of suctioned blood during cardiopulmonary bypass impairs hemostasis. Ann Thorac Surg1995;59:901–7.
22.
InoueT, SakaiY, HoshiK, YaguchiI, FujitoT, MorookaS.Lower expression of neutrophil adhesion molecule indicates less vessel wall injury and might explain lower restenosis rate after cutting balloon angioplasty. Circulation1998;97(25):2511–8.
23.
HindmarshEJ, MarksRM. Complement activation occurs on subendothelial extracellular matrix in vitro and is initiated by retraction or removal of overlying endothelial cells. J Immunol1998;160(12):6128–36.
24.
HarboeM.A method for determination of hemoglobin in plasma by near-ultraviolet spectrophotometry. Scand J Clin Lab1959;11:66–70.
25.
HemmilaI, DakubuS, MukkalaVM, SiitariH, LovgrenT.Europium as a label in time-resolved immunofluorometric assays. Anal Biochem1984;137(2):335–43.
26.
de ScheerderI, WangK, WilczekK, MeulemanD, van AmsterdamR, VogelG, PiessensJ, van de WerfF.Experimental study of thrombogenicity and foreign body reaction induced by heparin-coated coronary stents. Circulation1997;95(6):1549–53.
27.
GuYJ, van OeverenW, AkkermanC, BoonstraPW, HuyzenRJ, WildevuurChRH. Heparin-coated circuits reduce the inflammatory response to cardiopulmonary bypass. Ann Thorac Surg1993;55:917–22.
28.
GibbonsGH, DzauVJ. Molecular therapies for vascular diseases. Science1996;272(5262):689–93.
29.
TeirsteinPS, MassulloV, JaniS, PopmaJJ, MintzGS, RussoRJ, SchatzRA, GuarneriEM, SteutermanS, MorrisNB, . Catheter-based radiotherapy to inhibit restenosis after coronary stenting. N Engl J Med1997;336(24):1697–703.
30.
VerinV, UrbanP, PopowskiY, SchwagerM, NouetP, DorsazPA, ChatelainP, KurtzJM, RutishauserW.Feasibility of intracoronary beta-irradiation to reduce restenosis after balloon angioplasty. A clinical pilot study. Circulation1997;95(5):1138–44.
31.
WuKK, ThiagarajanP.Role of endothelium in thrombosis and hemostasis. Annu Rev Med1996;47:315–31.
32.
VanhouttePM. Hypercholesterolaemia, atherosclerosis and release of endothelium-derived relaxing factor by aggregating platelets. Eur Heart J1991;12 Suppl E:25–32.
33.
CABRI Trial Participants. First-year results of CABRI (Coronary Angioplasty versus Bypass Revascularisation Investigation). Lancet1995;346(8984):1179–84.
34.
QuyyumiAA, DakakN, AndrewsNP, GilliganDM, PanzaJA, CannonRO 3d. Contribution of nitric oxide to metabolic coronary vasodilation in the human heart. Circulation1995;92(3):320–6.
35.
CaramoriPRA, LimaVC, SeidelinPH, . Endothelial dysfunction distal to stents implanted for more than six months [abstract]. Circulation1997;96(8):I-756.
36.
MonninkSHJ, van BovenAJ, TioRA, . Is coronary stenting the Titanic of endothelial function? [abstract]. Eur Heart J1998;19 abstract supplement:P2146 (385).
37.
van BeusekomHM, WhelanDM, HofmaSH, KrabbendamSC, van HinsberghV, VerdouwPD, van der GiessenWI. Long-term endothelial dysfunction is more pronounced after stenting than after balloon angioplasty in porcine coronary arteries. J Am Coll Cardiol1998;32(4):1109–17.
38.
PepineCJ, HolmesDRJ. Coronary artery stents. American College of Cardiology. J Am Coll Cardiol1996;28(3):782–94.
39.
HolmesDRJ, HirshfeldJJ, FaxonD, VlietstraRE, JacobsA, KingSB. ACC Expert consensus document on coronary artery stents. Document of the American College of Cardiology. J Am Coll Cardiol1998;32(5):1471–82.
